Cytokinetics Inc’s recently made public that its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $96120.0 on Feb 04 ’25. In the deal valued at $48.06 per share,2,000 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 116,071 shares worth roughly $4.9 million.
Then, Malik Fady Ibraham sold 2,000 shares, generating $91,840 in total proceeds. Upon selling the shares at $45.92, the EVP Research & Development now owns 116,071 shares.
Before that, Malik Fady Ibraham sold 2,000 shares. Cytokinetics Inc shares valued at $98,640 were divested by the EVP Research & Development at a price of $49.32 per share. As a result of the transaction, Malik Fady Ibraham now holds 116,071 shares, worth roughly $4.9 million.
Citigroup initiated its Cytokinetics Inc [CYTK] rating to a Buy in a research note published on February 07, 2025; the price target was $86. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. RBC Capital Mkts began covering CYTK with “an Outperform” recommendation on November 08, 2024. Goldman revised its rating on August 13, 2024. It rated CYTK as “a Neutral” which previously was an “a Buy”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -1.29% to $42.21. Over the last five days, the stock has lost -12.91%. Cytokinetics Inc shares have fallen nearly -10.27% since the year began. Nevertheless, the stocks have fallen -45.27% over the past one year. While a 52-week high of $81.36 was reached on 01/27/25, a 52-week low of $42.72 was recorded on 02/10/25. SMA at 50 days reached $48.51, while 200 days put it at $53.68.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 41.32, which if violated will result in even more drops to 40.44. On the upside, there is a resistance level at 43.48. A further resistance level may holdings at 44.75. The Relative Strength Index (RSI) on the 14-day chart is 33.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.45%. Stochastics %K at 6.94% indicates the stock is a buying.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-01-15, growing by 0.3 million shares to a total of 14.03 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 13.73 million shares. There was a rise of 2.14%, which implies that there is a positive sentiment for the stock.
